| Methods |
Six‐week double blind, randomised study. |
| Participants |
Psychiatric outpatients meeting DSM‐III for major depression.
Age range: not reported.
Exclusion criteria: not reported. |
| Interventions |
Fluvoxamine: 13 participants.
Imipramine: 11 participants.
Placebo: 13 participants.
Fluvoxamine dose range: not stated.
Imipramine dose range: not stated. |
| Outcomes |
HRSD (change score only). No tolerability data could be entered in a meta‐analysis were reported. |
| Funded by pharmaceutical companies |
No funding by pharmaceutical companies. |
| Fluvoxamine as an investigational or comparator drug |
Unclear. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Quote: "randomly assigned", no further details. |
| Allocation concealment (selection bias) |
Unclear risk |
No details. |
| Blinding (performance bias and detection bias)
All outcomes |
Low risk |
Quote: "double blind", "HRSD score were obtained by a research clinician unaware of treatment assignment". |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No missing outcome data. |
| Selective reporting (reporting bias) |
Unclear risk |
Insufficient information to permit judgement. |
